Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunovaccine, a clinical stage vaccine development company focused on the commercialisation of patented DepoVax vaccine delivery technology, has entered into a collaborative research agreement with Israel- based Vaxil BioTherapeutics (Vaxil) to explore the efficacy of Vaxil's cancer antigens in Immunovaccine's DepoVax vaccine enhancement platform.
Subscribe to our email newsletter
Marc Mansour, vice president of R&D at Immunovaccine, said: “Vaxil has an approach for identifying cancer antigens that get presented more efficiently by the MHC molecules. Vaxil’s long peptides are good candidates for formulation in our DepoVax platform making this an interesting research partnership”
Lior Carmon, founder and CEO of Vaxil, said: “In preclinical studies, the DepoVax delivery platform has a demonstrated ability to enhance vaccines, generating a prolonged immune response. We believe that this could fit well with our products and we look forward to making strong advances together in developing the next generation of cancer therapeutics.”